1. A pharmaceutical composition for treating cancer, wherein the target for administering the composition is one or more cells located in the pancreas, the composition comprising an anticancer agent and a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier comprises albumin, wherein the ratio of albumin to anticancer the agent is 9: 1 or less. 2. The pharmaceutical composition of claim 1, wherein the albumin is human serum albumin. The pharmaceutical composition according to claim 1, wherein the ratio (w / w) of albumin to the anticancer agent in the pharmaceutical composition is less than 9: 1.4. The pharmaceutical composition of claim 1, wherein the ratio (w / w) of albumin to the anticancer agent in the pharmaceutical composition is 9: 1.5. The pharmaceutical composition of claim 1, wherein the ratio (w / w) of albumin to the anticancer agent in the pharmaceutical composition is from 1: 1 to 9: 1.6. The pharmaceutical composition of claim 1, wherein the composition contains from 0.1 to 25% by weight of albumin. The pharmaceutical composition of claim 6, wherein the pharmaceutical composition comprises from 0.5 to 5% by weight of albumin. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises drops containing albumin and an anticancer agent. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises nanoparticles containing albumin and an anticancer agent. The pharmaceutical composition of claim 9, wherein the ratio (w / w) of albumin to the anticancer agent in the pharmaceutical composition is less than 9: 1.11. The pharmaceutical composition of claim 9, wherein1. Фармацевтическая композиция для лечения рака, где мишенью для введения данной композиции является одна или большее количество клеток, находящихся в поджелудочной железе, при этом композиция содержит противораковый агент и фармацевтически приемлемый носитель, где фармацевтически приемлемый носитель вклю
